US 12,187,786 B2
Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
Zenjiro Sampei, Shizuoka (JP); Xing'er Christine Koo, Singapore (SG); Katja Fink, Singapore (SG); and Roland Zuest, Singapore (SG)
Assigned to Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP); and Agency for Science, Technology and Research, Singapore (SG)
Filed by Chugai Seiyaku Kabushiki Kaisha, Tokyo (JP); and Agency for Science, Technology and Research, Singapore (SG)
Filed on Aug. 22, 2023, as Appl. No. 18/453,418.
Application 17/066,092 is a division of application No. 16/435,979, filed on Jun. 10, 2019, granted, now 10,844,113, issued on Nov. 24, 2020.
Application 18/453,418 is a continuation of application No. 17/066,092, filed on Oct. 8, 2020, granted, now 11,780,908.
Application 16/435,979 is a continuation of application No. 16/333,736, granted, now 10,604,561, issued on Mar. 31, 2020, previously published as PCT/SG2017/050465, filed on Sep. 15, 2017.
Claims priority of application No. 10201607778X (SG), filed on Sep. 16, 2016.
Prior Publication US 2024/0018219 A1, Jan. 18, 2024
Int. Cl. C07K 16/10 (2006.01); A61K 39/12 (2006.01); A61K 39/395 (2006.01); A61P 31/12 (2006.01); C07K 14/005 (2006.01); C07K 16/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/1081 (2013.01) [A61P 31/12 (2018.01); A61K 2039/505 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); Y02A 50/30 (2018.01)] 1 Claim
 
1. A process for preparing an antibody comprising: (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 12, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 15, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 20, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 21, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 24 and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 27, the process comprising the steps of:
(a) combining a VH variant sequence selected from the group consisting of: 3CH1047 (SEQ ID NO: 6), and 3CH1049 (SEQ ID NO: 95) with a human IgG1 CH sequence selected from the group consisting of: SG182 (SEQ ID NO: 46), SG1095 (SEQ ID NO: 54) and SG1106 (SEQ ID NO: 59);
(b) combining a VL variant sequence selected from the group consisting of 3CL (SEQ ID NO: 7) and 3CL633 (SEQ ID NO: 98), with a human CL sequence SK1 (SEQ ID NO: 60);
(c) cloning each one of the combinations in an expression vector;
(d) expressing the resulting expression vectors in co-transfected cells; and
(e) purifying the resulting antibody from step (d).